Management of Tardive Dyskinesia and Comorbidities

Author(s):

Jason Noel, PharmD, MPA, BCPP,Julie Dopheide, PharmD, BCPP, FASHP

Panelists discuss how managing tardive dyskinesia in patients with comorbid mental health conditions requires a delicate balance between treating TD symptoms while maintaining psychiatric stability, emphasizing the importance of coordinated care between psychiatrists and movement disorder specialists to optimize medication regimens, monitor for potential drug interactions, and address the complex interplay between physical symptoms and psychological well-being.

EP: 1.Optimizing Tardive Dyskinesia Care: Strategies to Advance Treatment Approaches

EP: 2.Diagnosing Tardive Dyskinesia

EP: 3.Impact of Tardive Dyskinesia on Quality of Life

EP: 4.Improving Outcomes Through Patient Education and Addressing Unmet Needs

EP: 5.Treatment Options for Tardive Dyskinesia

EP: 6.Long-Term Outcomes with VMAT2 Inhibitors

EP: 7.Safety Profile of VMAT2 Inhibitors and Impact on Treatment Selection

Now Viewing

EP: 8.Management of Tardive Dyskinesia and Comorbidities

EP: 9.Shared Decision-Making in Tardive Dyskinesia

EP: 10.Strategies for Optimizing Therapy

EP: 11.Patient Journey and the Role of the Pharmacist

EP: 12.Patient Counseling and Management of Adverse Events

EP: 13.Dosing and Titration Considerations

EP: 14.Enhancing Adherence and Collaborative Care

EP: 15.Educational Resources to Support Patients

Video series above is prompted by the following:

How does the burden of comorbid conditions, such as mental health disorders, influence the management and outcomes of patients with TD?
How does the long-term management of TD align with treatment strategies for other movement disorders, and what challenges or opportunities arise when managing coexisting conditions

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!